Advertisement

Topics

Merck and Aeglea study Keytruda combo for small cell lung cancer

14:40 EST 14 Nov 2017 | Elsevier Business Intelligence

Aeglea BioTherapeutics Inc. is pairing its arginase inhibitor AEB1102 (pegzilarginase) with Merck & Co. Inc.’s PD-1 inhibit...

Original Article: Merck and Aeglea study Keytruda combo for small cell lung cancer

NEXT ARTICLE

More From BioPortfolio on "Merck and Aeglea study Keytruda combo for small cell lung cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...